Smith & Nephew Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Smith & Nephew şirketinin kazançları yıllık ortalama -18.5% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 3.9% oranında artan oldu. Gelirler yıllık ortalama 3% oranında artan oldu. Smith & Nephew şirketinin öz sermaye getirisi 5.9% olup, net marjı 5.4% dir.

Anahtar bilgiler

-18.5%

Kazanç büyüme oranı

-18.5%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	-9.5%
Gelir büyüme oranı	3.0%
Özkaynak getirisi	5.9%
Net Marj	5.4%
Sonraki Kazanç Güncellemesi	25 Feb 2025

Yakın geçmiş performans güncellemeleri

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Recent updates

Investors Still Waiting For A Pull Back In Smith & Nephew plc (LON:SN.)

Oct 31

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Sep 25

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 11

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Aug 19

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Jul 17

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Jun 11

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

May 09

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Apr 09

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

Feb 09

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

Nov 21

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Nov 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Oct 26

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Aug 11

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Jul 28

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 26

Gelir ve Gider Dağılımı

Smith & Nephew nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

LSE:SN. Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
29 Jun 24	5,642	305	2,942	291
29 Mar 24	5,596	284	2,916	306
31 Dec 23	5,549	263	2,890	320
30 Sep 23	5,449	241	2,816	324
01 Jul 23	5,349	218	2,741	327
01 Apr 23	5,282	221	2,718	331
31 Dec 22	5,215	223	2,695	335
30 Sep 22	5,214	360	2,680	344
02 Jul 22	5,213	496	2,665	352
02 Apr 22	5,213	510	2,651	351
31 Dec 21	5,212	524	2,637	349
30 Sep 21	5,168	539	2,607	340
03 Jul 21	5,124	553	2,576	330
03 Apr 21	4,842	501	2,508	319
31 Dec 20	4,560	448	2,439	307
30 Sep 20	4,624	420	2,470	304
27 Jun 20	4,688	391	2,501	301
27 Mar 20	4,913	496	2,518	297
31 Dec 19	5,138	600	2,534	292
30 Sep 19	5,044	649	2,449	281
29 Jun 19	4,949	698	2,364	269
29 Mar 19	4,927	681	2,374	258
31 Dec 18	4,904	663	2,384	246
30 Sep 18	4,887	690	2,450	239
30 Jun 18	4,869	717	2,496	232
31 Mar 18	4,817	742	2,453	228
31 Dec 17	4,765	767	2,419	223
30 Sep 17	4,721	817	2,346	224
01 Jul 17	4,677	867	2,282	224
01 Apr 17	4,673	826	2,269	227
31 Dec 16	4,669	784	2,255	230
30 Sep 16	4,680	570	2,515	228
02 Jul 16	4,690	356	2,393	225
02 Apr 16	4,662	383	2,363	224
31 Dec 15	4,634	410	2,524	222
30 Sep 15	4,702	513	2,333	224
27 Jun 15	4,669	557	2,326	225
27 Mar 15	4,680	499	2,375	234
31 Dec 14	4,617	501	2,323	235
27 Sep 14	4,543	503	2,285	239
28 Jun 14	4,422	523	2,201	241
29 Mar 14	4,349	563	2,124	235
31 Dec 13	4,351	556	2,149	231

Kaliteli Kazançlar: SN. büyük bir tek seferlik zarar ile $264.0M, 29th June, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: SN. 'nin mevcut net kar marjları (5.4%) geçen yılın (4.1%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SN. şirketinin kazançları son 5 yılda yılda 18.5% oranında azaldı.

Büyüme Hızlandırma: SN. 'un son bir yıldaki kazanç büyümesi ( 39.9% ) 5 yıllık ortalamasını (yıllık -18.5% ) aşıyor.

Kazançlar vs. Sektör: SN. geçen yılki kazanç büyümesi ( 39.9% ) Medical Equipment sektörünün 39.9% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: SN. 'nin Özsermaye Getirisi ( 5.9% ) düşük olarak değerlendiriliyor.

Smith & Nephew Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

First half 2024 earnings: EPS exceeds analyst expectations

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Full year 2023 earnings: EPS misses analyst expectations

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Recent updates

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 15%

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Investors Still Waiting For A Pull Back In Smith & Nephew plc (LON:SN.)

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Consensus EPS estimates fall by 16%

First half dividend of US$0.14 announced

First half 2024 earnings: EPS exceeds analyst expectations

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Consensus EPS estimates increase by 11%

Smith & Nephew (LON:SN.) Will Be Hoping To Turn Its Returns On Capital Around

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Consensus EPS estimates fall by 21%

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings: EPS misses analyst expectations

Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Is Smith & Nephew (LON:SN.) Using Too Much Debt?

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Consensus EPS estimates increase by 10%

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Now 22% undervalued

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

High number of new directors

CEO & Director exercised options to buy UK£59k worth of stock.